Akcea Therapeutics Inc (AKCA) Stock Price, Forecast & Analysis

NASDAQ:AKCA

18.17
+0.03 (+0.17%)
At close: Oct 9, 2020
18.15
-0.02 (-0.11%)
After Hours: 10/9/2020, 8:24:15 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News

AKCA Key Statistics, Chart & Performance

Key Statistics
Market Cap1.85B
Revenue(TTM)336.56M
Net Income(TTM)-41.52M
Shares101.60M
Float94.87M
52 Week High21.71
52 Week Low8
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.54
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
AKCA short term performance overview.The bars show the price performance of AKCA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

AKCA long term performance overview.The bars show the price performance of AKCA in the last 1, 2 and 3 years. 1 year 2 years 3 years -2 -4 -6

The current stock price of AKCA is 18.17 null. In the past month the price increased by 0.17%. In the past year, price decreased by -8%.

Akcea Therapeutics Inc / AKCA Daily stock chart

AKCA Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to AKCA. When comparing the yearly performance of all stocks, AKCA is one of the better performing stocks in the market, outperforming 76.92% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
AKCA Full Technical Analysis Report

AKCA Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to AKCA. AKCA has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
AKCA Full Fundamental Analysis Report

AKCA Financial Highlights

Over the last trailing twelve months AKCA reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 65.82% compared to the year before.


Industry RankSector Rank
PM (TTM) -12.34%
ROA -7.86%
ROE N/A
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-60%
Sales Q2Q%-15.95%
EPS 1Y (TTM)65.82%
Revenue 1Y (TTM)53.07%
AKCA financials

AKCA Forecast & Estimates


Analysts
Analysts60
Price TargetN/A
EPS Next Y-445.83%
Revenue Next YearN/A
AKCA Analyst EstimatesAKCA Analyst Ratings

AKCA Ownership

Ownership
Inst Owners0.01%
Ins Owners76.83%
Short Float %N/A
Short RatioN/A
AKCA Ownership

About AKCA

Company Profile

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Company Info

Akcea Therapeutics Inc

22 BOSTON WHARF RD 9TH FLOOR

BOSTON MA 02210

CEO: Damien McDevitt

Phone: 617-207-0202

Akcea Therapeutics Inc / AKCA FAQ

What does AKCA do?

Akcea Therapeutics, Inc. is a biopharmaceutical company. It focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. The Company's drug pipeline consists of volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx which are in clinical stage. Akcea Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.


What is the current price of AKCA stock?

The current stock price of AKCA is 18.17 null. The price increased by 0.17% in the last trading session.


Does AKCA stock pay dividends?

AKCA does not pay a dividend.


What is the ChartMill rating of Akcea Therapeutics Inc stock?

AKCA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Where is Akcea Therapeutics Inc (AKCA) stock traded?

AKCA stock is listed on the Nasdaq exchange.